These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11223660)

  • 41. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
    Ezekowitz MD; Cappato R; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca MI; Vardas PE; Kirchhof P; Hohnloser SH; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M
    Am Heart J; 2014 May; 167(5):646-52. PubMed ID: 24766973
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of silent microembolism by magnetic resonance imaging after cardioversion in atrial fibrillation.
    Vázquez M; Santos E; Rodriguez I; Pato A; Vilar M; Arias JC; Fernández R; Costas I; Ghioldi A; Sanmartin M; Tardáguila F
    Rev Esp Cardiol (Engl Ed); 2012 Feb; 65(2):139-42. PubMed ID: 22153725
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The predictive value of C-reactive protein on recurrence of atrial fibrillation after cardioversion with or without treatment with atorvastatin.
    Höglund N; Andersson J; Almroth H; Tornvall P; Englund A; Rosenqvist M; Jensen SM; Boman K
    Int J Cardiol; 2013 Sep; 167(5):2088-91. PubMed ID: 22704860
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Atrial and ventricular volume and function evaluated by magnetic resonance imaging in patients with persistent atrial fibrillation before and after cardioversion.
    Therkelsen SK; Groenning BA; Svendsen JH; Jensen GB
    Am J Cardiol; 2006 Apr; 97(8):1213-9. PubMed ID: 16616028
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effects of left ventricular diastolic function on natriuretic peptide levels after cardioversion of atrial fibrillation.
    Bakowski D; Wozakowska-Kapłon B; Opolski G
    Kardiol Pol; 2009 Apr; 67(4):361-7. PubMed ID: 19492248
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study).
    Sorino M; Colonna P; De Luca L; Carerj S; Oliva E; De Tommasi SM; Conti U; Iacopi F; D'Agostino C; D'Amato N; Pettinati G; Montericcio V; Cualbu A; De Luca I
    J Cardiovasc Med (Hagerstown); 2007 Dec; 8(12):1034-42. PubMed ID: 18163016
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prognostic impact of successful cardioversion of atrial fibrillation in patients with organic heart disease.
    Kleemann T; Becker T; Dönges K; Vater M; Gut B; Schneider S; Senges J; Seidl K
    Clin Res Cardiol; 2007 Feb; 96(2):103-8. PubMed ID: 17115325
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Myoglobin and troponin I as markers of myocardial damage during cardioversion of atrial fibrillation].
    Kosior D; Chwyczko T; Stawicki S; Tadeusiak W; Rabczenko D; Opolski G
    Pol Arch Med Wewn; 2003 Aug; 110(2):827-36. PubMed ID: 14682220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Electrical cardioversion for atrial fibrillation].
    Laszlo R; Laszlo S; Graze H; Schreieck J
    Dtsch Med Wochenschr; 2010 Apr; 135(15):750-4. PubMed ID: 20373272
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pre-treatment with Irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation.
    Dagres N; Karatasakis G; Panou F; Athanassopoulos G; Maounis T; Tsougos E; Kourea K; Malakos I; Kremastinos DT; Cokkinos DV
    Eur Heart J; 2006 Sep; 27(17):2062-8. PubMed ID: 16891381
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Role amiodarone in sinus rhythm maintenance after successful cardioversion in patients with chronic non-valvular atrial fibrillation].
    Kosior D; Szulc M; Zawadzka M; Pierścińska M; Stawicki S; Rabczenko D; Torbicki A; Opolski G
    Pol Arch Med Wewn; 2002 Dec; 108(6):1151-60. PubMed ID: 12687927
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Atrial fibrillation patients with CHA2DS2-VASc >1 benefit from oral anticoagulation prior to cardioversion.
    Själander S; Svensson PJ; Friberg L
    Int J Cardiol; 2016 Jul; 215():360-3. PubMed ID: 27128562
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of transesophageal echocardiography guided cardioversion in patients with atrial fibrillation, previous left atrial thrombus and effective anticoagulation.
    Saeed M; Rahman A; Afzal A; Agoston I; Jammula P; Birnbaum Y; Ware DL; Uretsky BF; Schwarz ER; Rosanio S
    Int J Cardiol; 2006 Nov; 113(3):401-5. PubMed ID: 16822564
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reverse electrical remodeling of the atria post cardioversion in patients who remain in sinus rhythm assessed by signal averaging of the P-wave.
    Chalfoun N; Harnick D; Pe E; Undavia M; Mehta D; Gomes JA
    Pacing Clin Electrophysiol; 2007 Apr; 30(4):502-9. PubMed ID: 17437574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Haemostatic activity in patients with atrial fibrillation treated with low-molecular-weight heparin before and after electrical cardioversion.
    Zeuthen EL; Lassen JF; Husted SE
    J Thromb Thrombolysis; 2004 Jun; 17(3):185-9. PubMed ID: 15353916
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
    Lip GYH; Al-Saady N; Jin J; Sun M; Melino M; Winters SM; Zamoryakhin D; Goette A
    Am J Cardiol; 2017 Sep; 120(5):792-796. PubMed ID: 28709650
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serial antiarrhythmic therapy: role of amiodarone in prevention of atrial fibrillation recurrence--a lesson from the HOT CAFE Polish Study.
    Kosior DA; Opolski G; Wozakowska-Kaplon B; Rabczenko D;
    Cardiology; 2005; 104(1):35-44. PubMed ID: 15942183
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Strokes after cardioversion of atrial fibrillation--The FibStroke study.
    Palomäki A; Mustonen P; Hartikainen JE; Nuotio I; Kiviniemi T; Ylitalo A; Hartikainen P; Lehtola H; Luite R; Airaksinen KE
    Int J Cardiol; 2016 Jan; 203():269-73. PubMed ID: 26519683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Silent embolism after electrical cardioversion of atrial fibrillation: what does brain magnetic resonance imaging provide?
    Arias MA; Casares-Medrano J; Pachón M; Puchol A
    Rev Esp Cardiol (Engl Ed); 2012 May; 65(5):489; author reply 490. PubMed ID: 22401762
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.